It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Marburg and Ebola filoviruses are two of the deadliest infectious agents and several outbreaks have occurred in the last decades. Although several receptors and co-receptors have been reported for Ebola virus, key host factors remain to be elucidated. In this study, using a haploid cell screening platform, we identify the guanine nucleotide exchange factor CCZ1 as a key host factor in the early stage of filovirus replication. The critical role of CCZ1 for filovirus infections is validated in 3D primary human hepatocyte cultures and human blood-vessel organoids, both critical target sites for Ebola and Marburg virus tropism. Mechanistically, CCZ1 controls early to late endosomal trafficking of these viruses. In addition, we report that CCZ1 has a role in the endosomal trafficking of endocytosis-dependent SARS-CoV-2 infections, but not in infections by Lassa virus, which enters endo-lysosomal trafficking at the late endosome stage. Thus, we have identified an essential host pathway for filovirus infections in cell lines and engineered human target tissues. Inhibition of CCZ1 nearly completely abolishes Marburg and Ebola infections. Thus, targeting CCZ1 could potentially serve as a promising drug target for controlling infections caused by various viruses, such as SARS-CoV-2, Marburg, and Ebola.
Host factors involved in filovirus infection are incompletely understood. Here, the authors used a haploid cell screening system to unveil CCZ1’s crucial role in regulating endosomal trafficking thus virus movement within cells and thereby impacting Marburg and Ebola infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
2 National Veterinary Institute, Uppsala, Sweden (GRID:grid.419788.b) (ISNI:0000 0001 2166 9211)
3 University of Padova, Department of Molecular Medicine, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
4 Institute of Molecular Biotechnology of the Austrian Academy of Science, IMBA, Vienna, Austria (GRID:grid.417521.4) (ISNI:0000 0001 0008 2788); Doctoral School of the University of Vienna and Medical University of Vienna, Vienna BioCenter PhD Program, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492)
5 Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
6 Public Health Agency of Sweden, Solna, Sweden (GRID:grid.419734.c) (ISNI:0000 0000 9580 3113)
7 Acus Laboratories GmbH, Cologne, Germany (GRID:grid.4714.6); JLP Health GmbH, Vienna, Austria (GRID:grid.4714.6)
8 Institute of Molecular Biotechnology of the Austrian Academy of Science, IMBA, Vienna, Austria (GRID:grid.417521.4) (ISNI:0000 0001 0008 2788)
9 Acus Laboratories GmbH, Cologne, Germany (GRID:grid.24381.3c); JLP Health GmbH, Vienna, Austria (GRID:grid.24381.3c)
10 Justus Liebig University, Institute for Virology, FB10-Veterinary Medicine, Giessen, Germany (GRID:grid.8664.c) (ISNI:0000 0001 2165 8627)
11 Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); University Tübingen, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany (GRID:grid.502798.1) (ISNI:0000 0004 0561 903X)
12 Acus Laboratories GmbH, Cologne, Germany (GRID:grid.502798.1); JLP Health GmbH, Vienna, Austria (GRID:grid.502798.1)
13 National Institutes of Health, Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Hamilton, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
14 Institute of Molecular Biotechnology of the Austrian Academy of Science, IMBA, Vienna, Austria (GRID:grid.417521.4) (ISNI:0000 0001 0008 2788); University of British Columbia, Department of Medical Genetics, Life Sciences Institute, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830); Medical University of Vienna, Department of Laboratory Medicine, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492); Helmholtz Centre for Infection Research, Braunschweig, Germany (GRID:grid.7490.a) (ISNI:0000 0001 2238 295X)
15 Karolinska Institute and Karolinska University Hospital, Department of Laboratory Medicine, Unit of Clinical Microbiology, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); National Veterinary Institute, Uppsala, Sweden (GRID:grid.419788.b) (ISNI:0000 0001 2166 9211); Public Health Agency of Sweden, Solna, Sweden (GRID:grid.419734.c) (ISNI:0000 0000 9580 3113)